Content deleted Content added
Logo change Tags: Incorrectly formatted external link or image Visual edit |
FDA approval of Pretomanid |
||
Line 39:
TB Alliance has the largest pipeline of TB drugs in history<ref name=":0" /> and part of TB Alliance’s stated mission is to ensure that any new treatments are affordable and accessible in the [[developing world]], and that they are adopted as soon as they become available.<ref>{{Cite web|url=https://www.tballiance.org/about/mission|title=About TB Alliance|website=TB Alliance|language=en|access-date=2019-04-25}}</ref> Pricing terms are included in all licensing contracts and end products are designed to be easy for patients to take. TB Alliance also collaborates with national and international partners, working to ensure that new therapies are adopted and accessible to [[healthcare provider]]s and patients via local channels.
In February 2019, TB Alliance’s application for the novel tuberculosis (TB) medicine [[pretomanid]] was accepted for review by the U.S. FDA. In August 2019, TB Alliance's tuberculosis (TB) medicine [[pretomanid tables]] was approved by the U.S. FDA, to be used in conjunction with two other antibiotics, for the treatment of an extremely drug-resistant strain of TB. <ref name=":1">{{Cite web|url=https://www.tballiance.org/news/pretomanid-enters-FDA-review|title=TB Medicine Pretomanid Enters Regulatory Review Process in the United States {{!}} TB Alliance|website=www.tballiance.org|access-date=2019-04-25}}</ref> If approved, the drug would be indicated for use as part of a new regimen, in combination with [[bedaquiline]] and [[linezolid]], for treatment of extensively drug-resistant (XDR) TB as well as treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB.<ref name=":1" />
==Treating Drug-Resistant TB==
| |||